Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Working Capital Changes (2019 - 2025)

Northwest Biotherapeutics (NWBO) has 11 years of Other Working Capital Changes data on record, last reported at -$8000.0 in Q3 2025.

  • For Q3 2025, Other Working Capital Changes fell 144.44% year-over-year to -$8000.0; the TTM value through Sep 2025 reached -$11000.0, down 104.76%, while the annual FY2024 figure was $64000.0, 73.55% down from the prior year.
  • Other Working Capital Changes reached -$8000.0 in Q3 2025 per NWBO's latest filing, down from $58000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $125000.0 in Q4 2023 and bottomed at -$42000.0 in Q2 2021.
  • Average Other Working Capital Changes over 5 years is $26210.5, with a median of $35000.0 recorded in 2022.
  • Peak YoY movement for Other Working Capital Changes: plummeted 171.19% in 2021, then surged 275.0% in 2022.
  • A 5-year view of Other Working Capital Changes shows it stood at $27000.0 in 2021, then skyrocketed by 37.04% to $37000.0 in 2022, then soared by 237.84% to $125000.0 in 2023, then plummeted by 133.6% to -$42000.0 in 2024, then surged by 80.95% to -$8000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were -$8000.0 in Q3 2025, $58000.0 in Q2 2025, and -$19000.0 in Q1 2025.